Medinol

Executive Summary

Medinol is an Israeli privately-held medtech company that designs, develops, manufactures, and commercializes advanced cardiovascular interventional devices. Founded in 1992 and based in Tel Aviv, the company employs 200-500 people and operates at the commercial stage. Its product portfolio includes drug-eluting coronary and peripheral stents, transcatheter aortic valve replacement (TAVR) systems, and implantable microsensors. Medinol's core technology leverages electrospinning elastomeric coatings, hybrid scaffold designs, and miniaturized passive sensors, which collectively enhance device deliverability, visibility, and physiological monitoring capabilities. The company's innovations aim to address key challenges in interventional cardiology, such as restenosis, thrombosis, and real-time pressure monitoring. Medinol's competitive advantages stem from its proprietary electrospinning platform and sensor integration, which set it apart from conventional stent manufacturers. With over three decades of experience, the company has built a robust intellectual property portfolio and established a global presence, though it remains privately held. The company's growth prospects are supported by expanding indications for its TAVR systems and the growing demand for minimally invasive cardiovascular procedures. However, as a private entity, financial details and pipeline transparency are limited. Medinol's success will depend on its ability to gain regulatory approvals in key markets and secure strategic partnerships for distribution and commercialization.

Upcoming Catalysts (preview)

• Q2 2027FDA or CE Mark approval for next-generation drug-eluting stent with electrospinning coating65% success
• Q4 2026Clinical trial results for transcatheter aortic valve replacement (TAVR) system with integrated sensor50% success
• Q1 2027Strategic licensing or distribution partnership for implantable microsensor technology70% success